In this Q&A, you’ll hear from Caitlin Baltzer, co-founder and CEO of MYndspan, a scientifically validated platform for preventative brain scans and analysis. Preparing a London debut for the first consumer clinic to use magnetoencephalography (MEG) technology, Caitlin shares how decoding brain function will be the next big thing in longevity and wellness.
Tell us about MYndspan.
Caitlin Baltzer: MYndspan is building the future of preventive and proactive brain health. We are the first company to bring magnetoencephalography (MEG)—the gold standard in brain function imaging—directly to the public.
Until now, MEG has been confined to elite research labs and specialist clinics. Transforming breakthrough technology into a consumer-ready product, we’re making it fast, accessible, and actionable. In just 45 minutes, users receive a comprehensive brain health report, including Functional Brain Age, Brain Stability Index, and insights into neural network function — empowering them to optimize cognitive performance, track early signs of decline, and take control of their mental well-being.
Most imaging scans like MRI or CT only show structure. Our MEG scans show function — in real time, with millisecond and millimeter precision, while capturing how your brain is aging, how stable its networks are, and how it’s functioning in everyday states like focus or rest.
We’re also preparing the world’s first commercial MEG brain scanning site in London. The experience is simple: a 10-minute, noninvasive, silent scan combined with gamified cognitive tests and a lifestyle assessment. Within 24 hours, users receive a report with actionable insights to guide decisions on everything from sleep to therapy to brain training.
What led you to pursue this opportunity?
CB: MYndspan was born out of a shared insight between myself and my co-founder Janne Huhtala.
I was VP of Operations at brain imaging company Croton Healthcare and Janne was CEO of MEGIN, a leader in MEG hardware. During the due diligence of Croton’s acquisition of MEGIN, both of us were struck by a simple truth: MEG was too powerful to remain locked away in labs.
As we worked alongside world-class neuroscientists discovering biomarkers for conditions like Alzheimer’s and PTSD, we knew there was a bigger opportunity — one that extended beyond diagnosis to prevention and optimization.
We founded MYndspan to unlock MEG for everyone. Our mission is to make brain health as trackable and normalized as physical health — to help people feel better, think clearer, and stay sharper, longer.
Proof of early impact, 89% of our customers say their scan gave them more clarity, confidence, and control over their brain health.
How did you turn your idea into a company?
CB: We began by validating the science through partnerships with world-renowned researchers using MEG to identify functional biomarkers of brain aging, concussion, and neurodegeneration.
Our early studies, published in Imaging Neuroscience and NeuroImage: Clinical, demonstrated MEG’s ability to detect changes in brain function — before symptoms emerged.
Next, we built a consumer-ready product that pairs a clinical-grade MEG scan with cognitive testing and lifestyle assessments, delivering insights like Functional Brain Age and Brain Stability Index — all in under an hour.
We’ve now scanned over 580 individuals and leveraged 2K+ research datasets to deliver the most advanced, accessible brain scan on the market. We’ve also built the world’s largest privately held MEG dataset, with applications for clinical, wellness, and research use cases.
Finally, we continue to secure key infrastructure and distribution partnerships across the MEG industry (MEGIN, IMEDCO), precision neuroscience (BIOS Health), and clinic networks (Re:Cognition Health).
With early product-market fit, high user retention, and a waitlist approaching 2K people in the UK, we’re launching our flagship brain health center — and laying the foundation for global expansion.
How big can this get?
CB: Cognitive decline is a global health crisis, with one in three people experiencing a neurodegenerative condition, at a cost burden of $2.5T annually. But nearly 45% of dementia cases are preventable with early detection and intervention.
Right now, there’s no routine, accessible way to track brain health until it’s too late. MYndspan fills this gap.
We’re building the leading, scientifically validated platform for preventive brain scans and analysis. Our scan detects early changes in brain function that other tools miss — giving individuals and clinicians the ability to take action sooner.
So, we sit at the intersection of two fast-growing markets: Brain health and longevity—where demand is rising for early, accurate diagnostics—and the $6.3T wellness industry, where consumers actively seek tools to stay sharper, longer.
Companies like Neko Health, Ezra, and Prenuvo have proven the model for preventive imaging and health. MYndspan is doing the same for the brain.
How do you reach your core customer?
CB: Our core customer is someone who wants to take an active role in their brain health — whether they’re noticing subtle changes, have a family history of neurodegeneration, or simply want to stay sharper for longer.
These individuals are typically health-conscious, data-driven, and proactive. Many come to us because they’re looking for more than what traditional brain health assessments offer, especially earlier in life before symptoms appear. Others are looking to better understand how stress, lifestyle, or previous injuries may be impacting their cognition.
We’re currently acquiring customers through a combination of:
- Waitlist sign-ups and early access campaigns
- Earned media and partnerships with leading wellness and clinical voices
- Clinician referrals from neurologists and integrative health providers
- Targeted outreach to high-interest groups, such as mid-life professionals, athletes, and individuals with a family history of cognitive decline
Our flagship brain health center in London is our first step in building a global platform. From here, we plan to expand across the UK, North America, and Europe through a mix of owned locations and clinical partnerships.
As we scale, our goal is to make MYndspan’s scan as routine and accessible as a full-body MRI — starting with those most motivated to understand and protect their brain health.
What’s next on the roadmap?
CB: In the next six months, we’re opening our London brain health center, the first of its kind worldwide, while expanding partnerships with leading companies in MEG infrastructure and neurotech analysis to build a true end-to-end brain health platform.
Our platform is built for scale — and our data model gets stronger with every scan.
Anything else you’d like to share with readers?
CB: This month, we’re launching a crowdfunding campaign on Crowdcube to support the opening of our flagship brain health center in London.
We’ve had incredible support so far — from the MEG community, our early users, and a growing waitlist of people who want better answers about their brain health. With that momentum, we felt it was the perfect time to open up this opportunity for others to get involved.
Crowdcube is a platform for UK-based investors only, which makes sense for this first phase of growth as we build our foundation in London.
But we’re already planning what comes next, and we’ll be sharing more soon about our expansion into the US and beyond. If you want to be among the first to experience a MYndspan scan, join our waitlist to get in the queue for London or through one of our research partners.
If you’re interested in having your company featured in our Q&A series, send an email to team@fitt.co.
